A method to quantitatively measure the response of a patient to an immune-modulator drug, the method comprising the following steps: a. Activating peripheral blood mononuclear cells (PBMCs), total leukocytes or specific sub-populations of PBMCs such as T-lymphocytes, regulatory T cells (Tregs), NK (Natural Killer cells), macrophages or B-lymphocytes, obtained from a biological sample selected from the list consisting of blood or blood cellular derivatives of the patient, though incubation with a lymphocyte activation compound selected from the list consisting of: agonistic antibodies anti CD3 and anti CD28, ionomycin and PMA (phorbol myristate acetate), lectins, superantigens, Lipopolysaccharides, antigen determinants or epitopes or through a Mix Lymphocyte Reaction; b. Obtaining a hydrogel which in turn comprises the activated PBMCs, total leukocytes or specific sub-populations of PBMCs, embedded within the hydrogel, wherein the hydrogel is located in a support characterized by having a dimensional proportions in which one of the spatial three axes (longitudinal axis) is at least 4 times longer than the length average of the two other axes, so that the hydrogel is capable of providing a measurable and stable drug gradient flux in the major axis of the described channelled wells, wherein the channelled wells contain a hydrogel volume per channel of at least 40 μl and wherein the channelled well should be covered completely by the hydrogel in its longitudinal axis and should cover at least 30% of the channelled well height; c. Contacting the hydrogel of step b) with one or more immune-modulator drugs; d. Adding a solution of a compound capable of revealing an inhibitory zone around the site of contact of the immunosuppressant drug with the hydrogel; e. Obtaining the quantification of the immune-modulator drug gradient formed, preferably by image acquisition or signal quantification (absorbance, fluorescence or luminescence); wherein the hydrogel is formed through non-covalent crosslinking (physical hydrogels) of polymer chains, wherein the total polymeric fraction represents less than 5% (5 gr/ 100 ml of hydrogel), and wherein the total polymeric fraction consists of methyl cellulose and collagen, wherein methyl cellulose content is equal or below 4% (gr/ 100 ml of hydrogel), preferably below or equal to 2% (gr/ 100 ml of hydrogel), and collagen content is below or equal to 0.3% (gr/ 100 ml of hydrogel). a. Activating peripheral blood mononuclear cells (PBMCs), total leukocytes or specific sub-populations of PBMCs such as T-lymphocytes, regulatory T cells (Tregs), NK (Natural Killer cells), macrophages or B-lymphocytes, obtained from a biological sample selected from the list consisting of blood or blood cellular derivatives of the patient, though incubation with a lymphocyte activation compound selected from the list consisting of: agonistic antibodies anti CD3 and anti CD28, ionomycin and PMA (phorbol myristate acetate), lectins, superantigens, Lipopolysaccharides, antigen determinants or epitopes or through a Mix Lymphocyte Reaction; b. Obtaining a hydrogel which in turn comprises the activated PBMCs, total leukocytes or specific sub-populations of PBMCs, embedded within the hydrogel, wherein the hydrogel is located in a support characterized by having a dimensional proportions in which one of the spatial three axes (longitudinal axis) is at least 4 times longer than the length average of the two other axes, so that the hydrogel is capable of providing a measurable and stable drug gradient flux in the major axis of the described channelled wells, wherein the channelled wells contain a hydrogel volume per channel of at least 40 μl and wherein the channelled well should be covered completely by the hydrogel in its longitudinal axis and should cover at least 30% of the channelled well height; c. Contacting the hydrogel of step b) with one or more immune-modulator drugs; d. Adding a solution of a compound capable of revealing an inhibitory zone around the site of contact of the immunosuppressant drug with the hydrogel; e. Obtaining the quantification of the immune-modulator drug gradient formed, preferably by image acquisition or signal quantification (absorbance, fluorescence or luminescence);